On December 7, 2016, the U.S. Senate approved the 21st Century Cures Act, a wide-ranging health bill whose passage ensured the American government's commitment to curing cancer. President Barack Obama signed the bill into law soon there after.
The 21st Century Cures Act, sponsored by U.S. Rep. Fred Upton (R-MI), invests more than $6.5 billion in a variety of healthcare initiatives, including funding for cancer research. Among the ways it will affect our field’s future is enhancing the ability to more effectively use large volumes of data toward clinical advancements in cancer research, spark development of precision medicine, and accelerates the pace of clinical trials through the required use of centralized institutional review boards.
SITC joined 20 other cancer-focused organizations in a letter publicly declaring support for the Cures Act.
The letter – sent by the NCCR, an advocacy companion organization of the National Coalition for Cancer Research – stressed the critical importance of the bill, including investing in the future of biomedical research with an emphasis on promoting young investigators in the cancer research field.
Click here to read the NCCR letter.
In January 2016, then-President Barack Obama announced a $1B National Cancer Moonshot Initiative. The initiative, led by former Vice President Joe Biden, aims to accelerate research efforts and break down barriers to progress by enhancing data access, and facilitating collaborations with researchers, doctors, philanthropies, patients, and patient advocates, and biotechnology and pharmaceutical companies. The overarching goal is to bring about a decade’s worth of advances in five years, making more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.
Vice President Biden is moving forward with his efforts to focus upon ending cancer as a part of his priorities during his last year in office and beyond. Immunotherapy, genomics and combination therapies are central to these research efforts.
Throughout 2016, SITC leaders participated in the Cancer Moonshot as the collective voice for the field of cancer immunotherapy. SITC involvement has taken shape in the following ways:
On June 29, 2016, Biden convened a Cancer Moonshot Summit in Washington, D.C. SITC was represented by the society's Executive Director, Tara Withington, CAE along with other SITC members in attendance. In connection with the D.C. summit, SITC hosted a virtual Twitter summit to foster discussion amongst members, colleagues, patients, and advocates.
On October 17, 2016, Biden delivered the Cancer Moonshot report to the President and the American public. The report summarizes the work of the Cancer Moonshot Task Force since its creation in January, and lays out the Vice President’s strategic plan for transforming cancer research and care. The report also includes the Cancer Moonshot Blue Ribbon Panel’s identified areas of scientific opportunity. SITC leaders including Executive Director Tara Withington, CAE were in attendance onsite.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com